Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01379469 · ClinicalTrials.gov registry record · Phase 2
Carbamazepine in Severe Liver Disease Due to Alpha-1 Antitrypsin Deficiency
A Phase 2 study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT01379469 is a Phase 2 study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 20 participants.
The verdict
NCT01379469, a Phase 2 study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The primary objective is to determine if the medication Carbamazepine, can be used as a therapy for patients with severe liver disease due to Alpha-1-Antitrypsin Deficiency .
Interventions
- DRUG Drug-Carbamazepine (Tegretol XR)
- DRUG Carbamazepine (Tegretol XR) Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2012-01 |
| Est. Completion | 2017-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01379469
The ClinicalTrials.gov registry entry for NCT01379469 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Drug-Carbamazepine (Tegretol XR) is the first listed.
NCT01379469 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01379469 about?
NCT01379469 is a clinical study titled "Carbamazepine in Severe Liver Disease Due to Alpha-1 Antitrypsin Deficiency". The primary objective is to determine if the medication Carbamazepine, can be used as a therapy for patients with severe liver disease due to Alpha-1-Antitrypsin Deficiency .
What is the current status of trial NCT01379469?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2012-01. Estimated completion is 2017-02.
What interventions are being tested in trial NCT01379469?
The interventions under investigation include: Drug-Carbamazepine (Tegretol XR) (DRUG), Carbamazepine (Tegretol XR) Placebo (DRUG).
Who is sponsoring clinical trial NCT01379469?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.